CTS Corporation is a global manufacturer of sensors connectivity components and actuators. The company was established in 1896 as a provider of high-quality telephone products and was incorporated as an Indiana corporation in February 1929. Its principal executive offices are located in Lisle Illinois. CTS Corporation designs manufactures and sells a broad line of sensors connectivity components and actuators primarily to original equipment manufacturers tier one suppliers for the aerospace and defense industrial medical transportation markets and...
CTS Corporation is a global manufacturer of sensors connectivity components and actuators. The company was established in 1896 as a provider of high-quality telephone products and was incorporated as an Indiana corporation in February 1929. Its principal executive offices are located in Lisle Illinois. CTS Corporation designs manufactures and sells a broad line of sensors connectivity components and actuators primarily to original equipment manufacturers tier one suppliers for the aerospace and defense industrial medical transportation markets and the U. S. Government. The company’s vision is to be a leading provider of sensing and motion devices as well as connectivity components enabling an intelligent and seamless world. These devices are categorized by their ability to Sense Connect or Move. Sense products provide vital inputs to electronic systems. Connect products allow systems to function in synchronization with other systems. Move products ensure required movements are effectively and accurately executed. CTS Corporation is committed to achieving its vision by continuing to invest in the development of products technologies and talent within these categories. It operates manufacturing facilities in North America Asia and Europe. Sales and marketing are accomplished through its sales engineers independent manufacturers representatives and distributors.
CTS Corporation generates revenue primarily from the sale of its sensors connectivity components and actuators to original equipment manufacturers tier one suppliers distributors and the U. S. Government. Products are grouped into Sense Connect and Move families. The Sense family includes controls pedals piezo sensing products sensors switches transducers. The Connect family includes EMI/RFI filters capacitors frequency control products resistors RF filters. The Move family includes piezo microactuators rotary actuators. In 2025 transportation accounted for 43 percent of net sales industrial 26 percent medical 16 percent and aerospace and defense 15 percent. Revenue is also derived through its sales engineers independent manufacturers representatives and distributors with approximately 86 percent of 2025 net sales attributable to sales engineers 7 percent to independent distributors and 7 percent to independent manufacturers representatives.
CTS Corporation competes with domestic and foreign manufacturers on product features technology price quality reliability delivery and service. Most product lines encounter competition globally with the number of competitors varying across lines. No single competitor competes with the company in every product line but some competitors are larger and more diversified. The company believes it competes most successfully in custom engineered products manufactured to meet specific applications of major OEMs. Additionally the company faces risks of technical obsolescence and pressure from customers seeking lower cost and higher quality reliability and delivery standards.
The company’s customer base includes original equipment manufacturers tier one suppliers distributors and the U. S. Government. Significant customers in 2025 were Toyota Motor Corporation representing 11.2 percent of total net sales and Cummins Inc representing 8.4 percent. No other customer accounted for ten percent or more of total net sales in those years. CTS Corporation also works with global and regional distributors such as Avnet Inc Digi-Key Electronics Master Electronics Future Electronics and TTI Inc. It serves aerospace and defense industrial medical transportation markets and government agencies.
CTS’s diversified end‑market portfolio now accounts for almost 60% of revenue, a dramatic shift from its historical transportation focus. The company’s 16% YoY growth in this diversified segment is fueled by double‑digit increases in medical therapeutics, industrial automation, and aerospace & defense. Management consistently highlighted these high‑margin sectors as core growth engines, and the book‑to‑bill ratio above 1.00 indicates sustained demand. This structural realignment positions CTS to capture expanding industrial digitization trends and a growing healthcare market that favors precision sensing solutions.
Medical therapeutics sales jumped 41% in Q4 and 21% for the full year, driven by the firm’s advanced transducer technology. The company’s partnership with leading device manufacturers to embed sensors in pacemakers, cochlear implants, and minimally invasive imaging platforms suggests a deepening of the value chain. CTS’s focus on “mission‑critical” healthcare solutions also provides a defensive moat, as such products tend to receive stable reimbursement and high switching costs. Furthermore, the company’s commitment to expanding diagnostic capabilities, particularly portable ultrasound, positions it to tap into the point‑of‑care trend and capture significant upside as healthcare systems shift toward value‑based care.
Industrial segment sales rose 16% QoQ and 12% YoY, reflecting a recovery from the prior year’s cyclical dip. CTS’s emphasis on temperature, frequency, and vibration sensing aligns with automation and energy‑efficiency megatrends. The addition of a new customer in the distribution channel and wins in heat‑pump and commercial appliance applications demonstrate the breadth of its industrial footprint. As global manufacturing leans more heavily on smart sensors for process optimization, CTS’s diversified product portfolio should benefit from increased capital expenditure in industrial automation.
Aerospace & defense sales grew 20% YoY, and the SideQuest operation adds a high‑margin, long‑duration revenue stream tied to government contracts. Although the company noted timing variations in funding cycles, its backlog remains near $1 billion, providing visibility for future cash flows. Defense programs are typically multi‑year and less sensitive to short‑term economic swings, which helps stabilize earnings during periods of automotive slowdown. The firm’s ongoing investments in RF filters and underwater locator beacons further diversify its defense portfolio and create opportunities for cross‑selling within existing contracts.
The company’s gross margin expanded by 150 basis points YoY to 39.1% in Q4, a significant improvement attributed to both operational efficiencies and a favorable product mix. CTS has demonstrated an ability to shift from low‑margin transportation components to higher‑margin medical and defense systems, thereby improving overall profitability. Management’s focus on cost control, coupled with the adoption of powertrain‑agnostic sensors, suggests that margin expansion can continue as the company scales its diversified product lines. The improved margin also supports robust free cash flow, enabling continued capital allocation to share buybacks and dividends.
CTS’s diversified end‑market portfolio now accounts for almost 60% of revenue, a dramatic shift from its historical transportation focus. The company’s 16% YoY growth in this diversified segment is fueled by double‑digit increases in medical therapeutics, industrial automation, and aerospace & defense. Management consistently highlighted these high‑margin sectors as core growth engines, and the book‑to‑bill ratio above 1.00 indicates sustained demand. This structural realignment positions CTS to capture expanding industrial digitization trends and a growing healthcare market that favors precision sensing solutions.
Medical therapeutics sales jumped 41% in Q4 and 21% for the full year, driven by the firm’s advanced transducer technology. The company’s partnership with leading device manufacturers to embed sensors in pacemakers, cochlear implants, and minimally invasive imaging platforms suggests a deepening of the value chain. CTS’s focus on “mission‑critical” healthcare solutions also provides a defensive moat, as such products tend to receive stable reimbursement and high switching costs. Furthermore, the company’s commitment to expanding diagnostic capabilities, particularly portable ultrasound, positions it to tap into the point‑of‑care trend and capture significant upside as healthcare systems shift toward value‑based care.
Industrial segment sales rose 16% QoQ and 12% YoY, reflecting a recovery from the prior year’s cyclical dip. CTS’s emphasis on temperature, frequency, and vibration sensing aligns with automation and energy‑efficiency megatrends. The addition of a new customer in the distribution channel and wins in heat‑pump and commercial appliance applications demonstrate the breadth of its industrial footprint. As global manufacturing leans more heavily on smart sensors for process optimization, CTS’s diversified product portfolio should benefit from increased capital expenditure in industrial automation.
Aerospace & defense sales grew 20% YoY, and the SideQuest operation adds a high‑margin, long‑duration revenue stream tied to government contracts. Although the company noted timing variations in funding cycles, its backlog remains near $1 billion, providing visibility for future cash flows. Defense programs are typically multi‑year and less sensitive to short‑term economic swings, which helps stabilize earnings during periods of automotive slowdown. The firm’s ongoing investments in RF filters and underwater locator beacons further diversify its defense portfolio and create opportunities for cross‑selling within existing contracts.
The company’s gross margin expanded by 150 basis points YoY to 39.1% in Q4, a significant improvement attributed to both operational efficiencies and a favorable product mix. CTS has demonstrated an ability to shift from low‑margin transportation components to higher‑margin medical and defense systems, thereby improving overall profitability. Management’s focus on cost control, coupled with the adoption of powertrain‑agnostic sensors, suggests that margin expansion can continue as the company scales its diversified product lines. The improved margin also supports robust free cash flow, enabling continued capital allocation to share buybacks and dividends.
Transportation revenue has declined 7% YoY and remains flat QoQ, reflecting an entrenched slowdown in commercial and light‑vehicle demand. The firm’s reliance on automotive OEMs, many of whom are recalibrating EV launch schedules, exposes CTS to cyclical volatility that is not fully mitigated by its diversified portfolio. Management’s comments on a “slightly down” outlook for the light‑vehicle market and the need to “wait a few quarters” before confirming a bottom highlight the uncertainty surrounding this core segment. If automotive volume declines persist, the company may face a prolonged period of under‑performance that could erode its recently improved margins.
SideQuest revenue was lower than expected due to timing of government funding, and management was explicit that this is “a little lighter” in 2025. Defense contracts are highly susceptible to budgetary cycles and political decisions, making revenue recognition unpredictable. The company’s backlog of $1 billion is a mitigating factor, but the lack of clarity on when funding will be fully released creates a risk of delayed cash flows and potential write‑downs. Moreover, the firm’s statements that it “expects the normalisation” in 2026 may be overly optimistic, given the volatile nature of defense spending across different jurisdictions.
The company’s expansion into new product lines, such as floor hinge technology and advanced drive‑pad systems, will not generate revenue until 2028. These long lead times introduce uncertainty into the revenue forecast and make it difficult to match current earnings expectations. Management’s emphasis on “future” product launches without providing concrete revenue estimates suggests a potential overreliance on yet‑to‑be‑proven solutions. This reliance on long‑cycle innovations could be a drag on profitability if market adoption stalls or if competitors release superior alternatives sooner.
CTS’s heavy investment in strategic acquisitions is hampered by high valuations across the market, as management admitted that “valuations are still high.” The firm’s pursuit of niche transportation technologies and complementary medical solutions could result in overpayment and integration challenges, diluting shareholder value. The current debt level of $58 million on a $82 million cash balance gives a moderate leverage ratio, but future acquisition financing could increase debt and strain cash flow, particularly if growth targets are not met. Such financial risk limits the company’s ability to continue its aggressive M&A strategy.
The company’s guidance for 2026 assumes “current market conditions continue,” but several macro‑economic variables—such as supply‑chain disruptions, rare‑earth metal shortages, and geopolitical tensions—could adversely impact production volumes and cost structures. Management has not provided a detailed risk mitigation plan for these contingencies. A persistent supply‑chain bottleneck could erode gross margins, especially if the firm’s automotive and defense customers tighten their own cost pressures. This risk is compounded by the company's dependence on semiconductors and other critical components, which have seen volatility in pricing and availability.
Transportation revenue has declined 7% YoY and remains flat QoQ, reflecting an entrenched slowdown in commercial and light‑vehicle demand. The firm’s reliance on automotive OEMs, many of whom are recalibrating EV launch schedules, exposes CTS to cyclical volatility that is not fully mitigated by its diversified portfolio. Management’s comments on a “slightly down” outlook for the light‑vehicle market and the need to “wait a few quarters” before confirming a bottom highlight the uncertainty surrounding this core segment. If automotive volume declines persist, the company may face a prolonged period of under‑performance that could erode its recently improved margins.
SideQuest revenue was lower than expected due to timing of government funding, and management was explicit that this is “a little lighter” in 2025. Defense contracts are highly susceptible to budgetary cycles and political decisions, making revenue recognition unpredictable. The company’s backlog of $1 billion is a mitigating factor, but the lack of clarity on when funding will be fully released creates a risk of delayed cash flows and potential write‑downs. Moreover, the firm’s statements that it “expects the normalisation” in 2026 may be overly optimistic, given the volatile nature of defense spending across different jurisdictions.
The company’s expansion into new product lines, such as floor hinge technology and advanced drive‑pad systems, will not generate revenue until 2028. These long lead times introduce uncertainty into the revenue forecast and make it difficult to match current earnings expectations. Management’s emphasis on “future” product launches without providing concrete revenue estimates suggests a potential overreliance on yet‑to‑be‑proven solutions. This reliance on long‑cycle innovations could be a drag on profitability if market adoption stalls or if competitors release superior alternatives sooner.
CTS’s heavy investment in strategic acquisitions is hampered by high valuations across the market, as management admitted that “valuations are still high.” The firm’s pursuit of niche transportation technologies and complementary medical solutions could result in overpayment and integration challenges, diluting shareholder value. The current debt level of $58 million on a $82 million cash balance gives a moderate leverage ratio, but future acquisition financing could increase debt and strain cash flow, particularly if growth targets are not met. Such financial risk limits the company’s ability to continue its aggressive M&A strategy.
The company’s guidance for 2026 assumes “current market conditions continue,” but several macro‑economic variables—such as supply‑chain disruptions, rare‑earth metal shortages, and geopolitical tensions—could adversely impact production volumes and cost structures. Management has not provided a detailed risk mitigation plan for these contingencies. A persistent supply‑chain bottleneck could erode gross margins, especially if the firm’s automotive and defense customers tighten their own cost pressures. This risk is compounded by the company's dependence on semiconductors and other critical components, which have seen volatility in pricing and availability.